ClinicalTrials.gg
CompletedNCT01911221Updated Jun 8, 2017Results posted

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

A Phase 3 interventional study of rMenB+OMV NZ in Prevention of the Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-08.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
21st of 21
13 · median 508
Started
2013
the only one that year
Phase 3
7 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
10 of 21
Novartis Vaccines

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 21st largest by enrollment, is the only one that started in 2013, is one of 7 in phase 3, and was the 11th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

The study will evaluate the immunogenicity and safety of the rMenB+OMV NZ in an adult population potentially at risk for meningococcal disease (e.g. lab workers).

03

Conditions studied

  • Prevention of the Meningococcal Disease

Keywords

  • Meningococcal disease,
  • Adults
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 - 65 years of age inclusive who have given written at the time of enrollment;
  2. Who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period);
  3. In good health as determined by medical history, physical examination and clinical judgment of the investigator;
  4. Who are or might be routinely exposed to cultures of N. meningitidis serogroup B.

Sponsor's employees are considered eligible to participate in the trial as per inclusion criteria.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or nursing (breastfeeding) mothers;
  2. Females of reproductive age who have not used or do not plan to use acceptable measures, for the 3 months duration of the study. Oral, injected or implanted hormonal contraceptive, diaphragm, condom, intrauterine device or sexual abstinence are considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods for at least 60 days prior to study entry;
  3. Any serious chronic or progressive disease according to judgment of the investigator (e.g. neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease);
  4. Individuals with history of any progressive or severe neurologic disorder, or seizure disorder. A single episode of febrile convulsion is not an exclusion criteria;
  5. History of any serogroup B meningococcal vaccine administration;
  6. Previous known or suspected disease caused by N. meningitidis;
  7. History of severe allergic reaction after previous vaccinations, or to any component of the vaccine;
  8. Known or suspected disease or impairment/alteration of the immune system resulting from (for example):

    • Receipt of any chronic therapy
    • Receipt of any chronic immunostimulants
    • Immune deficiency disorder, or known infection
  9. Subjects who are not able to comprehend and to follow all required study procedures for the whole period of the study;
  10. History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study;
  11. Any significant chronic infection;
  12. Known bleeding diathesis or any condition that may be associated with a prolonged bleeding time;
  13. Family members and household members of research staff;
  14. Participation in another clinical trial within the last 30 days or planned for during study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    rMenB+OMV NZ

    A single 0.5mL dose of the study vaccine will be administered intramuscularly in the deltoid muscle.

    Biological: rMenB+OMV NZ

Interventions

  • BiologicalrMenB+OMV NZ

    Drug page: 4CMenB vaccine

    Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain

06

What researchers measure

Primary outcomes

  1. Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule

    The immunogenicity was assessed to evaluate the human serum bactericidal activity (hSBA) against the indicator strains of N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and M10713 strain at baseline and at one month after the second vaccination.

    Time frame: Day1 and Day 91

  2. Geometric Mean Ratios Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule

    The immunogenicity was assessed to evaluate the hSBA in terms of geometric mean ratios within subjects against the indicator strains of N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 at one month after the second vaccination versus baseline.

    Time frame: Day1 and Day 91

  3. Percentages Of Subjects With hSBA≥ 1:5 Titers Against N Meningitidis Serogroup B Strains Following Two-Dose Vaccination Schedule.

    The immunogenicity was assessed to evaluate the hSBA titers ≥ 1:5 in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.

    Time frame: Day1 and Day91

  4. Percentages Of Subjects With hSBA≥ 1:8 Titers Against N Meningitidis Serogroup B Strains Following Two-Dose Vaccination Schedule.

    The immunogenicity was assessed to evaluate the human serum bactericidal activity titers ≥ 1:8 in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.

    Time frame: Day1 and Day91

  5. Percentages Of Subjects With Four-Fold Increase In Human Serum Bactericidal Activity From Baseline Against N Meningitidis Serogroup B Strains Following a Two Dose Vaccination Schedule.

    The antibody responses were assessed to evaluate the four fold increase in human serum bactericidal activity titers in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.

    Time frame: Day 91

  6. Geometric Mean Concentrations For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule

    The antibody responses were assessed to evaluate the geometric mean concentrations as measured by Enzyme Linked Immunosorbent Assay (ELISA) in terms of percentages of subjects for the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at baseline and at one month the second vaccination.

    Time frame: Day 1 and Day 91

  7. Geometric Mean Ratios For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.

    The antibody responses were assessed to evaluate the geometric mean ratios as measured by ELISA within the subjects for the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at one month after the second vaccination versus baseline.

    Time frame: Day 1 and Day 91

  8. Percentages of Subjects With Four Fold Increase From Baseline For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.

    The antibody responses were assessed to evaluate the four fold increases in ELISA concentrations as measured by ELISA to the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at one month the second vaccination over baseline.

    Time frame: Day 1 and Day 91

  9. Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination)

    The number of subjects with solicited local and systemic adverse events after receiving rMenB+OMV NZ (a two dose vaccination schedule) collected from day 1 through day 7 are reported.

    Time frame: Day 1 through Day 7 postvaccination.

  10. Number of Subjects Reporting Unsolicited Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination).

    Safety was assessed as the number of subjects who reported unsolicited adverse events as collected from Day 1 to Day 91 following rMenB+OMV vaccination (a two dose schedule). Unsolicited adverse events were collected from day 1 through day 7 after each vaccination, while serious adverse events, medically attended adverse events and adverse events leading to withdrawal from study were reported from day 1 through day 91.

    Time frame: Day 1 through Day 91 postvaccination.

  11. Number of Subjects Reporting Unsolicited Serious Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination).

    Safety was assessed as the number of subjects who reported Serious Adverse Events (SAEs), medically attended AEs, AEs leading to withdrawal from the study, as collected from day 1 to day 91 following vaccination with rMenB+OMV NZ (a two dose schedule ) are reported.

    Time frame: Day 1 through Day 91 postvaccination.

07

Results

Posted Oct 31, 2014

Participant flow

Subjects were recruited from single study center in Germany.

Participant flow — Overall Study
MilestonerMenB+OMV NZ
Started13
Completed13
Not completed0

Outcome measures

PrimaryGeometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule

The immunogenicity was assessed to evaluate the human serum bactericidal activity (hSBA) against the indicator strains of N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and M10713 strain at baseline and at one month after the second vaccination.

Time frame:
Day1 and Day 91
Reported as:
Geometric mean · Titers
Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule
TitersrMenB+OMV NZ
H44/76 Prevaccination (Day 1)1.18 (0.92 to 1.52)
Post 2nd vaccination (Day 91)53 (34 to 84)
5/99 Prevaccination (Day 1)2.27 (1.34 to 3.85)
After 2nd vaccination (Day 91)(N=12)143 (57 to 356)
NZ98/254 Prevaccination (Day 1)1.09 (0.91 to 1.31)
Post 2nd vaccination (Day 91)(N=12)15 (5.41 to 43)
M10713 Prevaccination (Day 1)21 (12 to 39)
Post second vaccination (Day 91)(N=12)56 (31 to 99)
PrimaryGeometric Mean Ratios Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule

The immunogenicity was assessed to evaluate the hSBA in terms of geometric mean ratios within subjects against the indicator strains of N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 at one month after the second vaccination versus baseline.

Time frame:
Day1 and Day 91
Reported as:
Geometric mean · ratio
Geometric Mean Ratios Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule
ratiorMenB+OMV NZ
H44/76 (Day 91/Day 1)45 (29 to 70)
5/99 (Day 91/Day 1)(N=12)59 (21 to 166)
NZ98/254 (Day 91/Day 1)(N=12)14 (5.17 to 37)
M10713 (Day 91/Day 1)(N=12)2.99 (1.43 to 6.27)
PrimaryPercentages Of Subjects With hSBA≥ 1:5 Titers Against N Meningitidis Serogroup B Strains Following Two-Dose Vaccination Schedule.

The immunogenicity was assessed to evaluate the hSBA titers ≥ 1:5 in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.

Time frame:
Day1 and Day91
Reported as:
Number · Percentages of subjects
Percentages Of Subjects With hSBA≥ 1:5 Titers Against N Meningitidis Serogroup B Strains Following Two-Dose Vaccination Schedule.
Percentages of subjectsrMenB+OMV NZ
H44/76 Prevaccination (Day 1)0 (0 to 25)
Post 2nd vaccination (Day 91)100 (75 to 100)
5/99 Prevaccination (Day 1)31 (9 to 61)
After 2nd vaccination (Day 91)(N=12)100 (74 to 100)
NZ98/254 Prevaccination (Day 1)0 (0 to 25)
Post 2nd vaccination (Day 91)(N=12)75 (43 to 95)
M10713 Prevaccination (Day 1)92 (64 to 100)
Post second vaccination (Day 91)(N=12)100 (74 to 100)
PrimaryPercentages Of Subjects With hSBA≥ 1:8 Titers Against N Meningitidis Serogroup B Strains Following Two-Dose Vaccination Schedule.

The immunogenicity was assessed to evaluate the human serum bactericidal activity titers ≥ 1:8 in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.

Time frame:
Day1 and Day91
Reported as:
Number · Percentage of Subjects
Percentages Of Subjects With hSBA≥ 1:8 Titers Against N Meningitidis Serogroup B Strains Following Two-Dose Vaccination Schedule.
Percentage of SubjectsrMenB+OMV NZ
H44/76 Prevaccination (Day 1)0 (0 to 25)
Post 2nd vaccination (Day 91)100 (75 to 100)
5/99 Prevaccination (Day 1)8 (0 to 36)
After 2nd vaccination (Day 91)(N=12)92 (62 to 100)
NZ98/254 Prevaccination (Day 1)0 (0 to 25)
Post 2nd vaccination (Day 91)(N=12)75 (43 to 95)
M10713 Prevaccination (Day 1)85 (55 to 98)
Post second vaccination (Day 91)(N=12)92 (62 to 100)
PrimaryPercentages Of Subjects With Four-Fold Increase In Human Serum Bactericidal Activity From Baseline Against N Meningitidis Serogroup B Strains Following a Two Dose Vaccination Schedule.

The antibody responses were assessed to evaluate the four fold increase in human serum bactericidal activity titers in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.

Time frame:
Day 91
Reported as:
Number · Percentage of subjects
Percentages Of Subjects With Four-Fold Increase In Human Serum Bactericidal Activity From Baseline Against N Meningitidis Serogroup B Strains Following a Two Dose Vaccination Schedule.
Percentage of subjectsrMenB+OMV NZ
H44/76100 (75 to 100)
5/99 (N=12)92 (62 to 100)
NZ98/254 (N=12)75 (43 to 95)
M10713 (N=12)33 (10 to 65)
PrimaryGeometric Mean Concentrations For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule

The antibody responses were assessed to evaluate the geometric mean concentrations as measured by Enzyme Linked Immunosorbent Assay (ELISA) in terms of percentages of subjects for the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at baseline and at one month the second vaccination.

Time frame:
Day 1 and Day 91
Reported as:
Geometric mean · U/mL
Geometric Mean Concentrations For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule
U/mLrMenB+OMV NZ
Prevaccination (Day 1)22 (18 to 28)
Post second vaccination (Day 91)1200 (537 to 2680)
PrimaryGeometric Mean Ratios For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.

The antibody responses were assessed to evaluate the geometric mean ratios as measured by ELISA within the subjects for the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at one month after the second vaccination versus baseline.

Time frame:
Day 1 and Day 91
Reported as:
Geometric mean · Ratio
Geometric Mean Ratios For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.
RatiorMenB+OMV NZ
Geometric Mean Ratios For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.54 (24 to 120)
PrimaryPercentages of Subjects With Four Fold Increase From Baseline For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.

The antibody responses were assessed to evaluate the four fold increases in ELISA concentrations as measured by ELISA to the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at one month the second vaccination over baseline.

Time frame:
Day 1 and Day 91
Reported as:
Number · Percentage of Subjects
Percentages of Subjects With Four Fold Increase From Baseline For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.
Percentage of SubjectsrMenB+OMV NZ
Percentages of Subjects With Four Fold Increase From Baseline For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.85 (55 to 98)
PrimaryNumber of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination)

The number of subjects with solicited local and systemic adverse events after receiving rMenB+OMV NZ (a two dose vaccination schedule) collected from day 1 through day 7 are reported.

Time frame:
Day 1 through Day 7 postvaccination.
Reported as:
Number · Number of Subjects
Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination)
Number of SubjectsrMenB+OMV NZ
Any local13
Injection site erythema0
Injection site swelling0
Injection site induration1
Injection site pain13
Any Systemic9
Nausea2
Myalgia3
Arthralgia3
Fatigue5
Headache8
Fever (≥38°C)1
Prophylactic use of antipyretics/analgesics0
Therapeutic use of antipyretics/analgesics4
PrimaryNumber of Subjects Reporting Unsolicited Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination).

Safety was assessed as the number of subjects who reported unsolicited adverse events as collected from Day 1 to Day 91 following rMenB+OMV vaccination (a two dose schedule). Unsolicited adverse events were collected from day 1 through day 7 after each vaccination, while serious adverse events, medically attended adverse events and adverse events leading to withdrawal from study were reported from day 1 through day 91.

Time frame:
Day 1 through Day 91 postvaccination.
Reported as:
Number · Number of subjects
Number of Subjects Reporting Unsolicited Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination).
Number of subjectsrMenB+OMV NZ
Any unsolicited AEs8
At least possibly related unsolicited AEs7
PrimaryNumber of Subjects Reporting Unsolicited Serious Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination).

Safety was assessed as the number of subjects who reported Serious Adverse Events (SAEs), medically attended AEs, AEs leading to withdrawal from the study, as collected from day 1 to day 91 following vaccination with rMenB+OMV NZ (a two dose schedule ) are reported.

Time frame:
Day 1 through Day 91 postvaccination.
Reported as:
Number · Number of subjects
Number of Subjects Reporting Unsolicited Serious Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination).
Number of subjectsrMenB+OMV NZ
AEs leading to study withdrawal0
Medically attended AEs2
Any SAEs0
At least possibly related SAEs0
AEs leading to death0

Adverse events

Collected over Day 1 through Day 91 postvaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rMenB+OMVNZ—0/13 (0%)13/13 (100%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventrMenB+OMVNZ
INJECTION SITE PAINGeneral disorders13/13
INJECTION SITE ERYTHEMAGeneral disorders10/13
HEADACHENervous system disorders8/13
FATIGUEGeneral disorders5/13
INJECTION SITE INDURATIONGeneral disorders5/13
INJECTION SITE SWELLINGGeneral disorders5/13
ARTHRALGIAMusculoskeletal and connective tissue disorders3/13
MYALGIAMusculoskeletal and connective tissue disorders3/13
NAUSEAGastrointestinal disorders2/13
RESPIRATORY TRACT INFECTIONInfections and infestations2/13

Baseline characteristics

Subjects received two doses of rMenB+OMV NZ at 0 month and 2 month schedule.

Age, Continuous
Age, Continuous(year)rMenB+OMV NZ
Mean38.5 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)rMenB+OMV NZ
FEMALE10
MALE3
08

Study locations

1 site
  • Novartis site
    Marburg, 35037, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2013
First posted
Jul 30, 2013
Start
Aug 2013
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Oct 31, 2014
Last update
Jun 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01911221
Lead sponsor
Novartis Vaccines
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 30, 2013
Start date
Aug 2013
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Oct 31, 2014
Last update
Jun 8, 2017

Study contacts

Novartis Vaccines and Diagnostics
study chair · Novartis Vaccines

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion